Anand Mahadevan, MD

My unique and innovative contribution in the area of Clinical Expertise is in the establishment of Stereotactic Body Radiotherapy, as a new and accepted modality, for cancer treatment. Over the past 17 years, I have endeavored to contribute to both the primary radiobiological understanding and clinical application of this new technology, specifically in the area of extra cranial Radiosurgery. My particular focus is on treating recurrent (often previously irradiated), spinal, liver and pancreatic cancers. Improved clinical outcomes have been achieved through the development and application of a dynamic “tolerance based” approach to determine optimal dosing regimens. This approach is increasingly viewed as the gold standard for guiding treatment in these types of clinical situations. The clinical innovations I have helped to develop are currently being tested in clinical trials, locally and nationally, and hopefully will be shown to be valid and applicable to a larger patient base. I have been fortunate to be able to present my unique clinical experience at local, regional and international meetings. 

I also actively participate in more oncology clinical research and serve the patient community. I was a co-investigator in several DFHCC and National Co-Operative Group Clinical trials and I have initiated clinical trials as a principal investigator. Until recently as part of Geisinger Cancer Institute, a recipient of NCORP grant, and Perlmutter Cancer Center, an NCI Designated Comprehensive Cancer Center, I am actively involved in clinical studies.